potential COVID-19 treatments - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.60 [0.45, 0.79]< 10%12 studies (12/-)100.0 %some concernlow moderatecrucial-
death or transfer to ICU 0.70 [0.44, 1.12]< 10%1 study (1/-)93.1 %NAnot evaluable crucial-
deaths 0.70 [0.59, 0.83]< 10%26 studies (26/-)100.0 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.68 [0.43, 1.08]< 10%4 studies (4/-)95.0 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.73 [0.51, 1.04]< 170%12 studies (12/-)95.9 %some concernlow moderateimportant-
clinical improvement 1.31 [1.09, 1.58]> 141%12 studies (12/-)99.8 %some concernlow moderateimportant-
clinical improvement (14-day) 1.17 [0.93, 1.47]> 135%9 studies (9/-)91.6 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %NAnot evaluable important-
clinical improvement (28-day) 1.34 [1.10, 1.62]> 146%5 studies (5/-)99.8 %some concernserious moderateimportant-
clinical improvement (7-day) 1.31 [1.01, 1.69]> 171%8 studies (8/-)98.1 %some concernserious moderateimportant-
clinical improvement (time to event analysis only) 1.28 [1.06, 1.54]> 154%7 studies (7/-)99.5 %some concernnot evaluable moderateimportant-
death or ventilation 0.75 [0.63, 0.88]< 10%5 studies (5/-)100.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.25 [0.92, 1.70]> 156%5 studies (5/-)92.7 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
mechanical ventilation 0.66 [0.37, 1.17]< 137%11 studies (11/-)92.3 %some concerncritical moderateimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %NAnot evaluable important-
radiologic improvement (14-day) 1.82 [0.95, 3.51]> 139%4 studies (4/-)96.4 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.09 [0.01, 0.78]> 10%2 studies (2/-)1.5 %some concernnot evaluable moderateimportant-
viral clearance 1.50 [1.08, 2.07]> 170%11 studies (11/-)99.3 %some concerncritical moderateimportant-
viral clearance (time to event analysis only) 1.13 [0.83, 1.55]> 156%3 studies (3/-)77.8 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.81 [0.10, 6.83]> 195%7 studies (7/-)42.2 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.17 [0.90, 1.53]> 160%9 studies (9/-)87.8 %some concernnot evaluable moderateimportant-
ICU admission 0.91 [0.67, 1.25]< 10%7 studies (7/-)71.5 %some concernnot evaluable moderatenon important-
recovery 1.13 [0.98, 1.31]> 10%3 studies (3/-)95.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.75 [0.54, 1.04]< 10%14 studies (14/-)95.8 %some concerncritical moderateimportant-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %NAnot evaluable non important-
adverse events 1.89 [1.34, 2.68]< 172%15 studies (15/-)0.0 %some concernlow moderatenon important-
arrhythmia 2.24 [0.23, 21.69]< 10%1 study (1/-)24.5 %NAnot evaluable non important-
elevated liver enzymes 3.48 [1.40, 8.64]< 10%1 study (1/-)0.4 %NAnot evaluable non important-
long QT 9.79 [1.27, 75.50]< 10%1 study (1/-)1.5 %NAnot evaluable non important-
Major bleeding 1.80 [0.88, 3.67]< 10%1 study (1/-)5.3 %NAnot evaluable non important-
renal impairment 1.35 [0.47, 3.86]< 10%1 study (1/-)28.8 %NAnot evaluable non important-

AE of interest endpoints 00

Thromboembolic events 0.89 [0.31, 2.55]< 10%1 study (1/-)58.6 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.